Trials / Active Not Recruiting
Active Not RecruitingNCT05972278
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
A Placebo-Controlled, Phase 1 Study to Investigate the Effect of Obicetrapib on Lipoprotein Metabolism.
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- NewAmsterdam Pharma · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
Detailed description
The study population will comprise 20 adults, 18 to 75 years of age, with LDL-C level ≥ 100 and ≤ 190 mg/dL, and in generally good health.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Obicetrapib | 1 tablet daily |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-09-26
- Completion
- 2024-10-14
- First posted
- 2023-08-02
- Last updated
- 2024-09-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05972278. Inclusion in this directory is not an endorsement.